Document:

Document

Exhibit 10.34

GRI BIO, INC.
Restricted Stock Award
This is a Restricted Stock Award dated as of December 7, 2022 from GRI Bio, Inc., a Delaware corporation (the “Corporation”), to W. Marc Hertz (“Grantee”).
1.    Definitions.  As used herein:  “Award” means the award of Restricted Stock hereby granted.
(a)    “Board” means the Board of Directors of the Corporation.
(b)    “Cause” means (i) misappropriation of any funds or property of the Corporation, theft, embezzlement or fraud, (ii) willful misconduct, gross negligence, or breach of fiduciary duty that, in each case or in the aggregate, results in material harm to the Corporation, (iii) conviction of a felony or (iv) any other misconduct by the Grantee that is materially injurious to the financial condition or business reputation of, or is otherwise materially injurious to, the Corporation.
(c)    “Change of Control” shall have the meaning set forth in the definition of “Liquidity Event” below.
(d)    “Code” means the Internal Revenue Code of 1986, as amended.
(e)    “Date of Grant” means December 7, 2022, the date on which the Corporation awarded the Restricted Stock.
(f)    “Disability” means “disability,” as such term is defined in Section 22(e)(3) of the Code.
(g)    “Employer” means the Corporation or a Subsidiary of the Corporation for which Grantee is performing services on the Vesting Date.
(h)    “IPO” means the date of the expiration of the lock-up period imposed on the Grantee following the completion of the Corporation’s first underwritten public offering of its common stock under the Securities Act of 1933, as amended. 
(i)    “Liquidity Event” means the first to occur of a Change of Control of the Corporation or an IPO.  The term “Change of Control” shall mean (i) the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than the Corporation or any stockholder of the Corporation of this Restricted Stock Award, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than 50% (on a fully diluted, as converted basis) of the outstanding voting securities of the Corporation; or (ii) the sale or other disposition by the Corporation of all or substantially all of its assets; or (iii) the merger or consolidation by the Corporation with or into another entity, as a result of which merger or consolidation, less than 50% of the voting securities of the surviving entity shall be owned by stockholders of the Corporation that were stockholders immediately prior to such merger or consolidation; or (iv) the dissolution, winding up or liquidation of the Corporation; provided, however, that, no Change of Control shall be deemed to occur by reason of the issuance by the Corporation of shares of the Corporation’s capital stock in connection with a capital-raising transaction.
(j)    “Performance Reasons” means (i) failure or refusal to faithfully and diligently perform the usual and customary duties for the Grantee’s employment, director or consulting relationship with the Corporation, and failure to remedy such failure or refusal within 15 days after receipt of written notice provided by the Corporation to the Grantee; or (ii) failure or refusal to materially comply with any reasonable policies, standards or regulations of the Corporation applicable to the Grantee, and failure to remedy such failure or refusal within 15 days after receipt of written notice provided by the Corporation to the Grantee.

(k)    “Restriction Period” means, with respect to each Share of Restricted Stock, the period beginning on the Date of Grant and ending on the applicable Vesting Date.
(l)    “Restricted Stock” means the 369,003 Shares which are the subject of the Award hereby granted.  As of the date of grant, the Restricted Stock is valued at $1.00 per share.
(m)    “Rule 16b-3” means Rule 16b-3 promulgated under the 1934 Act, as in effect from time to time.
(n)     “Securities Act” means the Securities Act of 1933, as amended.
(o)    “Share” or “Shares” means a share or shares of the Corporation’s common stock, par value $0.01 per share.
(p)    “Subsidiary” means, in respect of the Corporation or parent, a subsidiary company, whether now or hereafter existing, as defined in Sections 424(f) and (g) of the Code.
(q)    “Vesting Date” means the date of a Liquidity Event, or, if earlier, death or Disability of the Grantee or the termination by the Corporation or the Corporation’s shareholders, as applicable, of the Grantee’s service relationship with the Corporation, whether as an employee, member of the Board or consultant other than for Cause or Performance Reasons.
(r)    “1934 Act” means the Securities Exchange Act of 1934, as amended.
2.    Grant of Restricted Stock.  Subject to the terms and conditions set forth herein, the Corporation hereby grants to Grantee the Restricted Stock and Grantee hereby acknowledges the restrictions on the Restricted Stock.
3.    Restrictions on Restricted Stock.  Subject to the terms and conditions set forth herein and notwithstanding any other agreement to which the Grantee is a party, during the Restriction Period, Grantee shall not be permitted to sell, transfer, pledge, hypothecate, assign or otherwise dispose of the Restricted Stock.  The Corporation shall maintain possession of the certificates respecting the Restricted Stock during the Restriction Period.  Any attempted sale, transfer, pledge, hypothecation, assignment or other disposition of any Restricted Stock in violation of this Award shall be void and of no effect, and the Corporation shall have the right to disregard any such transfer on its books and records and to issue “stop transfer” instructions to its transfer agent, if any.
4.    Vesting.  Subject to the terms and conditions set forth herein, the restrictions set forth in Section 3 on each Share of Restricted Stock shall lapse on the Vesting Date if provided that throughout the Restriction Period, Grantee has continuously been an employee or director of, or consultant to, the Company or any Subsidiary.  Upon the lapse of the restrictions, subject to the terms of any applicable Shareholder’s Agreement, the Grantee will be free to hold, sell, transfer, pledge, assign or otherwise encumber the Shares.
5.    Forfeiture of Restricted Stock.  If Grantee’s employment or other service relationship with the Corporation and all Subsidiaries terminates during the Restriction Period for any reason other than death, Disability, involuntary termination by the Corporation (other than for Cause or Performance Reasons), including pursuant to a Change of Control or IPO, Grantee shall forfeit any Restricted Stock as of the date of such termination of employment or other service relationship.  Upon a forfeiture of the Restricted Stock as provided in this Section 5, the Restricted Stock shall be deemed canceled.  If Grantee’s employment or other service relationship with the Corporation and all Subsidiaries terminates during the Restriction Period as a result of death, Disability, involuntary termination by the Corporation (other than for Cause or Performance Reasons), including pursuant to a Change of Control or IPO, the restrictions on the Restricted Stock shall lapse as of the date of such termination of employment or other service relationship.
2

6.    Voting, Dividends and Recapitalization.  During the Restriction Period, Grantee shall have the right to vote the Restricted Stock and shall have the right to receive dividends, if any, paid on such Restricted Stock, in such amount and at such times as received by all other stockholders of the Corporation; provided that to the extent any such Shares of Restricted Stock are forfeited to the Corporation pursuant to Section 5 above, such rights shall terminate immediately with respect to the Shares of Restricted Stock that are so forfeited.  In the event of any changes in the capital stock of the Corporation by reason of any stock dividends, split-ups or combinations of shares, reclassifications, mergers, consolidations, reorganizations or liquidations while any shares comprising the Restricted Stock shall be subject to restrictions on transfer and forfeiture hereunder, any and all new, substituted or additional securities to which Grantee is entitled by reason of the ownership of such shares of Restricted Stock shall be subject immediately to the terms, conditions and restrictions of this Award.
7.    Notices.  For the purposes of this Award, notices and all other communications provided for in the Award shall be in writing and will be deemed to have been duly given when personally delivered, by facsimile transmission or sent by certified mail, return receipt requested, postage prepaid, or by expedited (overnight) courier with established national reputation, shipping prepaid or billed to sender, in either case addressed to the respective addresses last given by each party to the other (provided that all notices to the Corporation must be directed to the attention of the Secretary of the Corporation) or to such other address as either party may have furnished to the other in writing in accordance herewith.  All notices and communication will be deemed to have been received on the date of delivery thereof, or on the second day after deposit thereof with an expedited courier service, except that notice of change of address will be effective only upon receipt.
Corporation at:    GRI Bio, Inc.
2223 Avenida De La Playa
Suite 208
La Jolla, CA 92037
Grantee at:    The address in the Corporation’s records
8.    Applicable Laws.  The Corporation may from time to time impose any conditions on the Restricted Stock as it deems necessary or advisable to ensure that the Award satisfies the conditions of applicable laws.  In addition, the grant of Restricted Stock is intended to be exempt from the requirements of Section 409A of the Code, and, to the extent that further guidance is issued under Section 409A of the Code after the date of this Award, the Corporation may make any changes to this Award as are necessary to bring this Award into compliance with the applicable exemptions under Section 409A of the Code and the Treasury regulations issued thereunder.
9.    Delivery of Shares.  Except as otherwise provided in Section 8, upon the Vesting Date, the Corporation shall notify Grantee that the Restriction Period for the Restricted Stock has lapsed.  By the later of 10 business days following each Vesting Date, the Corporation will deliver to Grantee a certificate for the Restricted Stock without any legend or restrictions, except for such restrictions as may be imposed by the Corporation, in its sole judgment, under this Section 9, provided that no certificates for Shares will be delivered to Grantee until appropriate arrangements have been made with Employer for the withholding of any taxes which may be due with respect to such Shares.  The Corporation may condition delivery of certificates for Shares upon the prior receipt from Grantee of any undertakings which it may determine are required to assure that the certificates are being issued in compliance with federal and state securities laws.
10.    Stock Power; Power of Attorney.  Concurrent with the execution and delivery of this Award, and as an express condition to this Award, the Grantee shall deliver to the Corporation an executed stock power in the form attached hereto as Appendix A, in blank, with respect to the Restricted Stock.  The Grantee, by acceptance of this award, shall be deemed to appoint, and does so appoint by execution of this Award, the Corporation and each of its authorized representatives as the Grantee’s attorney(s)-in-fact to effect any transfer of unvested, forfeited shares to the Corporation as may be required or permitted pursuant to this Award and to execute such documents as the Corporation or such representative(s) deem necessary or advisable in connection with any such transfer.
3

11.    Tax Matters.  The Restricted Stock is intended to constitute property that is subject to a substantial risk of forfeiture during the Restriction Period, and subject to federal income tax in accordance with Section 83 of the Code.  Section 83 of the Code generally provides that Grantee will recognize compensation income with respect to each installment of Restricted Stock on such installment’s Vesting Date in an amount equal to the then fair market value of the shares for which restrictions have lapsed.  Alternatively, Grantee may elect, pursuant to Section 83(b) of the Code, to recognize compensation income for all or any part of the Restricted Stock at the Date of Grant in an amount equal to the fair market value of the Restricted Stock subject to the election on the Date of Grant.  Such election must be made within 30 days of the Date of Grant and Grantee shall immediately notify the Corporation if such an election is made.  Grantee should consult his or her tax advisors to determine whether a Section 83(b) election is appropriate.  If Grantee (after consulting with his or her tax advisors) decides to file an 83(b) election, then instructions and an election form are attached hereto as Appendix B.
12.    Award Not to Affect Employment.  The Award granted hereunder shall not confer upon Grantee any right to continue in the employment or other service relationship of the Corporation or any Subsidiary or affiliate of the Corporation.
13.    Securities Laws Representations.  
(a)    The Grantee acknowledges that the Shares of Restricted Stock have not been and will not be registered under the Securities Act or any other state securities laws, and therefore may not be resold without compliance with the Securities Act and the applicable state securities laws.  The Shares of Restricted Stock are being acquired solely for Grantee’s own account, for investment purposes only, and with no present intention of distributing, selling or otherwise disposing of it in connection with a distribution.
The Grantee covenants, warrants and represents that none of the Shares of Restricted Stock issued to Grantee will be offered, sold, assigned, pledged, hypothecated, transferred or otherwise disposed of except after full compliance with all of the applicable provisions of the Securities Act, the rules and regulations of the Securities and Exchange Commission and applicable state securities laws.  All the Restricted Stock shall bear the following legend in addition to any other legends required under this Award:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS (INCLUDING A VESTING SCHEDULE AND FORFEITURE PROVISION AND RESTRICTIONS AGAINST TRANSFER) CONTAINED IN A RESTRICTED STOCK AWARD BETWEEN GRI BIO, INC.  (THE “CORPORATION”) AND THE REGISTERED HOLDER, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE CORPORATION.
THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”) OR ANY STATE SECURITIES OR BLUE SKY LAWS.  SUCH SHARES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SHARES UNDER THE 1933 ACT AND ANY STATE SECURITIES OR BLUE SKY LAWS, UNLESS, IN THE OPINION (WHICH SHALL BE IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION) OF COUNSEL SATISFACTORY TO THE CORPORATION, SUCH REGISTRATION IS NOT REQUIRED.
(b)    The Grantee represents and warrants that (i) the Grantee has a preexisting personal or business relationship with the Corporation, including as a director of the Corporation, (ii) the Grantee has had an adequate opportunity to ask questions and receive answers from the officers of the Corporation concerning any and all matters relating to the transactions described herein including, without limitation, the background and experience of the current and proposed officers and directors of the Corporation, the plans for the operations of the business of the Corporation, and the business, operations and financial condition of the Corporation, and (iii) by reason of the Grantee’s business or financial experience, the Grantee has the capacity to protect the Grantee’s own interests in 
4

connection with this Award of Restricted Stock.  The Grantee acknowledges that he or she has adequate information concerning the restrictions placed upon the Shares of Restricted Stock hereunder.  In addition, the Grantee acknowledges that the Corporation is under no obligation to grant the Shares of Restricted Stock to Grantee.
(c)    The Corporation may from time to time impose any conditions on the Restricted Stock as it deems necessary or advisable to ensure that the Award satisfies the conditions of Rule 16b-3, and that Shares are issued and resold in compliance with the Securities Act.
(d)    The Grantee is aware that his, her or its investment in the Corporation is a speculative investment that has limited liquidity and is subject to the risk of complete loss.  The Grantee is able, without impairing his, her or its financial condition, to hold the Restricted Stock for an indefinite period and to suffer a complete loss of an investment in the Restricted Stock.
(e)    The Grantee agrees that the offer and sale of the Restricted Stock has not been accomplished by the publication of any advertisement.
14.    Miscellaneous.
(a)    Administration.  The administration of this Award shall be governed by the Board.  All decisions made by the Board shall be final and binding on all persons, including the Corporation and any Grantee.  No member of the Board shall be liable for any good faith determination, act or failure to act in connection with the Award.
(b)    Binding Effect.  Subject to the limitations set forth herein, this Award shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, legal representatives, successors and assigns.
(c)    Entire Agreement; Amendments.  This Award constitutes the entire agreement between the parties with respect to the Award and cannot be changed or terminated orally.  No modification or waiver of any of the provisions hereof shall be effective unless in writing and signed by the party against whom it is sought to be enforced.
(d)    Counterparts.  This Award may be executed in one or more counterparts, both of which taken together shall constitute one and the same agreement.
(e)    Governing Law.  This Award shall be governed and construed and the legal relationships of the parties determined in accordance with the internal laws of the State of Delaware.
(f)    Severability.  In the event that any provision in this Award shall be held invalid or unenforceable, such provision shall be severable from, and such invalidity or unenforceability shall not be construed to have any effect on, the remaining provisions of this Award.
(g)    Section Headings.  The captions and section headings of this Award are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.
(h)    Further Assurances.  Each of the parties hereto shall use its reasonable and diligent best efforts to proceed promptly with the transactions contemplated herein, to fulfill the conditions precedent for such party’s benefit or to cause the same to be fulfilled and to execute such further documents and other papers and perform such further acts as may be reasonably required or desirable to carry out the provisions hereof and the transactions contemplated herein.
(i)    Legal Counsel.  The Grantee and the Corporation recognize that this is a legally binding contract and acknowledge and agree that they have had the opportunity to consult with legal counsel of their choice.
5

						
	GRI BIO, INC.
		
	By:	/s/ W. Marc Hertz
		Name: W. Marc Hertz
		
		Title: President and Chief Executive Officer

6

ACKNOWLEDGMENT
The Grantee acknowledges receipt of the Restricted Stock Award, a copy of which is attached hereto; represents that he or she has read and is familiar with the terms and provisions thereof; hereby accepts this Grant subject to all of the terms and provisions thereof; and represents that Grantee’s representations in Section 13 thereof are true.  The Grantee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board of Directors upon any questions arising hereunder.
												
	Date:	December 7, 2022
		/s/ W. Marc Hertz
				Signature of Grantee
				
				W. Marc Hertz
				Name of Grantee

THE SHARES REPRESENTED BY THIS GRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE, TRANSFER OR DISTRIBUTION THEREOF.  NO SUCH SALE, TRANSFER OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATING THERETO OR A SATISFACTORY OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.
7

APPENDIX A

STOCK POWER
FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Award between Gri Bio, Inc. (the “Corporation”) and the individual named below (the “Individual”) dated as of December 7, 2022 the Individual hereby sells, assigns and transfers to the Corporation an aggregate _____ shares of common stock of the Corporation, standing in the Individual’s name on the books of Corporation and represented by stock certificate number(s) ____________________ to which this instrument is attached, and hereby irrevocably constitutes and appoints ____________________ as his or her attorney in fact and agent to transfer such shares on the books of the Corporation, with full power of substitution in the premises.
												
	Dated:			
				
				
				Signature
				
				
				Print Name

(Instruction: Please do not fill in any blanks other than the signature line.  The purpose of the assignment is to enable the Corporation to exercise its rights to reacquire the shares in the circumstances provided for in the Restricted Stock Award without requiring additional signatures on the part of the Individual.)
8

SECTION 83(b) ELECTIONS
INSTRUCTIONS REGARDING SECTION 83(b) ELECTIONS:
1.    An 83(b) Election is Irrevocable.
2.    If you choose to make an 83(b) Election, an 83(b) Election Form must be filed with the Internal Revenue Service within 30 days after the date the Restricted Stock is transferred to you.  No exceptions to this rule are made.
3.    You must provide a copy of the 83(b) Election Form to the corporate secretary or other designated officer of the Corporation.  This copy should be provided to the Corporation at the same time that you file your 83(b) Election Form with the Internal Revenue Service.
4.    In addition to making the filing under Item 2 above, you must attach a copy of your 83(b) Election Form to your tax return for the taxable year in which you received the restricted stock.
5.    If you make an 83(b) Election and later forfeit the Restricted Stock, you will not be entitled to a deduction with respect to the gross income you recognized under the 83(b) Election.
You are urged to consult your personal tax advisor before making an 83(b) Election to discuss the consequences thereof and consider whether such an election is advisable under the circumstances (and to complete the election form).
9

SECTION 83(b) ELECTION FORM
Election Pursuant to Section 83(b) of the Internal Revenue Code
to Include Property in Gross Income in Year of Transfer
The undersigned hereby makes an election pursuant to Section 83(b) of the Internal Revenue Code with respect to the property described below and supplies the following information in accordance with the regulations promulgated thereunder:
1.    The name, address, and taxpayer identification number of the undersigned are:
			
	
	
	

2.    Description of the property with respect to which the election is being made: ______ (___) shares of common stock, par value $0.01 per share, of __________.
3.    Date on which the property was transferred is: __________.
4.    The taxable year of the taxpayer in which this property was transferred is: ____.
5.    Nature of restrictions to which the property is subject: stock is subject to potential forfeiture pursuant to the trust indenture and is also subject to forfeiture for failure to remain employed by __________ during the __________ -year period following grant.
6.    The fair market value at the time of transfer (determined without regard to any restrictions other than restrictions which by their terms will never lapse) of the property with respect to which this election is being made is $__________ per share; with a cumulative fair market value of $__________.
7.    The taxpayer did not pay any amount for these shares.
8.    A copy of this statement was furnished to Gri Bio, Inc. for whom taxpayer rendered the services underlying the transfer of such property.
															
		Date			
					Name:

10Document

Exhibit 10.35

CONSULTING AND CLINICAL ADVISORY BOARD AGREEMENT
THIS CONSULTING AGREEMENT effective as of June 3, 2016 (the “Effective Date”), is between GRI Bio, Inc. (the “Company”), and Rohit Loomba, M.D. (the “Consultant”).
Recitals:
The parties wish to enter into this Agreement to set forth the basis on which the Consultant will perform consulting services for the Company and with respect to certain other matters in connection with such engagement, all as set forth more fully in this Agreement.
NOW, THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties to this Agreement hereby agree as follows:
1.Engagement.  The Company hereby engages the Consultant as a consultant to the Company and a Member of the Clinical Advisory Board, and the Consultant hereby accepts such engagement, on the terms and conditions set forth in this Agreement.
2.Duties.  As a consultant to the Company and Member of the Clinical Advisory Board, the Consultant agrees to provide consulting services relating to the planning and overall clinical and regulatory strategy for the drug development programs of Company.  In conjunction with these duties, the Consultant will:
•Provide critical review and comment on documents planned for submission to regulatory agencies.
•Provide advice and recommendations in addressing regulatory issues as they occur.
•Review clinical, medical, and regulatory data and questions prepared by GRI and submitted to Consultant in advance, and respond in face-to-face or remote presentations and discussions.
•Provide time, advice, and recommendations regarding other clinical and regulatory matters as the Company shall from time to time request.
3.Term and Termination.  The term of the Consultant’s engagement hereunder shall commence on the Effective Date and shall continue in effect until terminated as provided herein.  Either party may terminate this Agreement at any time upon 30 days’ written notice to the other party.  Either the Company or the Consultant may terminate this Agreement upon written notice in the event of a material breach of this Agreement, which breach is not cured within 30 days after written notice of the breach is provided by the terminating party.
4.Compensation.
(a)Fees.  The Company shall pay Consultant U.S. $500 per hour within 60 days after receipt of a detailed invoice from Consultant for Services; provided that in no event shall fees exceed $7,500 in any month or $75,000 per year without Company’s prior written approval.
(b)Option Grant.  Subject to approval by the Company’s Board of Directors, Consultant shall also receive a non-qualified option (the “Option”) to purchase 68,352 shares of Company Common Stock under Company’s 2015 Equity Incentive Plan.  The Option shall be subject to the execution by the Consultant of a nonqualified stock option agreement containing such terms and conditions as are determined by Company’s Board of Directors.  The per-share exercise price of the Options will be the fair market value on the date of grant, as determined by the Company’s Board of Directors.  The Option will vest as follows: 2,848 per month for 24 months; provided that the Consultant continues to serve as an employee of, or consultant to, Company on each respective vesting date.
(c)Reimbursement of Expenses.  The Consultant shall be reimbursed for out-of-pocket expenses reasonably incurred by the Consultant in performing the consulting services contemplated by this Agreement, provided that such expenses are pre-approved by the Company, documented and submitted in accordance with the reimbursement policies of the Company as in effect from time to time.  The parties agree that (i) the reimbursement of an expense pursuant to this Section 4(b) shall be provided not later than the calendar year following the calendar year in which the expense was incurred, (ii) the amount of expenses eligible for reimbursement during any calendar year may not affect the amount of expenses eligible for reimbursement in any 

other calendar year, and (iii) the right to reimbursement under this Section 5 is not subject to liquidation or exchange for another benefit.
(d)Entire Compensation.  Notwithstanding anything to the contrary set forth herein, the compensation provided for in this Section 4 shall constitute full payment for the services to be rendered by the Consultant to the Company hereunder.
5.Non-Disclosure.  The Consultant acknowledges that, in the course of performing services for the Company, the Consultant may obtain knowledge of the Company’s business plans, products, processes, software, know-how, trade secrets, formulas, methods, models, prototypes, discoveries, inventions, materials and reagents, improvements, disclosures, customer, contractor and supplier lists, names and positions of employees and/or other proprietary and/or confidential information (collectively, the “Confidential Information”).  The Consultant agrees to keep the Confidential Information secret and confidential and not to publish, disclose or divulge any Confidential Information to any other person, or use any Confidential Information for the Consultant’s own benefit or to the detriment of the Company, or for any purpose other than in connection with the performance of consulting services to the Company, without the prior written consent of the Company, whether or not such Confidential Information was discovered or developed by the Consultant.  The Consultant also agrees not to divulge, publish or use any proprietary and/or confidential information of others that the Company is obligated to maintain in confidence.
6.Intellectual Property Rights.
(a)Company Property.  All papers, records, data, reports, results, information, notes, drawings, files, documents, samples, devices, products, equipment, and other materials, including copies and in whatever form, relating to the business of the Company that Consultant generates as a result of performing the Services or that the Company gives to Consultant, whether or not confidential, and all intellectual property rights thereto, are the sole and exclusive property of the Company, and the Consultant hereby assigns and agrees to assign all right, title and interest therein to the Company.  In the event of the termination of the Consultant’s service to the Company, or the Company’s earlier request, the Consultant will promptly deliver all such materials to the Company.
(b)Inventions.  Any and all inventions, discoveries, know-how, trade secrets and the like, whether or not patentable, conceived, reduced to practice or otherwise made or generated by the Consultant, alone or in combination with others, as a result of performing the Services shall be the property of the Company (“Inventions”).  The Consultant hereby assigns and agrees to assign to the Company or its designee, without further consideration, the Consultant’s entire right, title and interest in and to all Inventions, including all rights to obtain, register, perfect and enforce patents, copyrights and other intellectual property protection for Inventions.  The Consultant shall promptly disclose in writing to an individual designated by the Company or to the Consultant’s immediate supervisor at the Company all Inventions.
(c)Assistance.  The Consultant further agrees to deliver to the Company any and all drawings, notes, specifications and data relating to each of the Inventions, and to sign, acknowledge and deliver all such further papers, including applications for and assignments of copyrights, patents and other intellectual property rights, and all renewals thereof, as may be reasonably requested to apply for or obtain copyrights, patents or other intellectual property rights for any and all of the Inventions in any and all jurisdictions and to vest title thereto in the Company and its successors and assigns and to otherwise protect the Company’s interests therein.
(d)Power of Attorney.  If the Company is unable, after reasonable effort, to secure the signature of the Consultant on any application for patent, copyright, trademark or other analogous registration or other documents regarding any legal protection relating to an Invention, for any reason whatsoever, the Consultant hereby irrevocably designates and appoints the President of the Company as the Consultant’s agent and attorney-in-fact, to act for and in the Consultant’s behalf and stead to execute and file any such application or applications or other documents and to do all other lawfully permitted acts to further the prosecution and issuance of patent, copyright, trademark or other registrations or any other legal protection thereon with respect to an Invention with the same legal force and effect as if executed by the Consultant.
(e)Company Documentation.  The Consultant shall hold in a fiduciary capacity for the benefit of the Company all documentation, programs, data, records, research materials, drawings, manuals, disks, reports, sketches, blueprints, letters, notes, notebooks and all other writings, electronic data, graphics and tangible information and materials of a secret, confidential or proprietary information nature relating to the Company or the Company’s business that are, at any time, in the possession or under the control of the Consultant.  The Consultant agrees that, in connection with any research, development or other services performed for the Company, the Consultant will maintain careful, adequate and contemporaneous written records of all Inventions, which records shall be the property of the Company.
2

7.Injunctive Relief.  The Consultant acknowledges that the Consultant’s compliance with the agreements in Sections 5 and 6 hereof is necessary to protect the goodwill and other proprietary interests of the Company and that the Consultant has been and will be entrusted with highly confidential information regarding the Company and its technology and is conversant with the Company’s affairs, its trade secrets and other proprietary information.  The Consultant acknowledges that a breach of any of the Consultant’s agreements in Sections 5 or 6 hereof may result in irreparable and continuing damage to the Company for which there will be no adequate remedy at law; and the Consultant agrees that, in the event of any breach of the aforesaid agreements, the Company and its successors and assigns shall be entitled to injunctive relief and to such other and further relief as may be proper.
8.Certain Representations, Warranties and Agreements of the Consultant.  As an inducement to the Company to enter into this Agreement, the Consultant hereby represents and warrants to the Company that: (a) the Consultant is not a party to or otherwise subject to any agreements or restrictions that would prohibit the Consultant from entering into this Agreement and carrying out the transactions contemplated by this Agreement in accordance with the terms hereof, and this Agreement and the transactions contemplated hereby will not infringe or conflict with, and are not inconsistent with, the rights of any other person or entity; (b) the Consultant has never been and is not currently: (i) an individual who has been debarred by the U.S. Food and Drug Administration (the “FDA”) pursuant to 21 U.S.C. 335a (a) or (b) (a “Debarred Individual”) from providing services in any capacity to a person that has an approved or pending drug product application, or (ii) an employer, employee or partner of a Debarred Individual; and (c) the Consultant has no knowledge of any circumstances that may affect the accuracy of the foregoing representations and warranties, including, but not limited to, FDA investigation of, or debarment proceedings against, the Consultant or any person or entity performing services or rendering assistance relating to activities taken pursuant to this Agreement, and the Consultant will immediately notify the Company if the Consultant becomes aware of any such circumstances during the term of this Agreement.  The Consultant agrees to immediately notify the Company if the Consultant becomes aware of any change in the representations and warranties set forth herein during the term of this Agreement.
9.Survival of Provisions.  The provisions of this Agreement that by their terms are intended to endure beyond the term of this Agreement shall survive the termination of this Agreement,
10.Supersedes Other Agreements.  This Agreement supersedes and is in lieu of any and all other consulting, employment and compensation arrangements between the Consultant and the Company, but shall not supersede any existing confidentiality, nondisclosure or invention assignment agreements between the Consultant and the Company.
11.Independent Contractor.  The parties intend that the Consultant shall render services hereunder as an independent contractor, and nothing herein shall be construed to be inconsistent with this relationship or status.  The Consultant shall not be entitled to any benefits paid by the Company to its employees.  The Consultant shall be solely responsible for any tax consequences applicable to the Consultant by reason of this Agreement and the relationship established hereunder, and the Company shall not be responsible for the payment of any federal, state or local taxes or contributions imposed under any employment insurance, social security, income tax or other tax law or regulation with respect to the Consultant’s performance of consulting services hereunder.
12.Amendments.  Any amendment to this Agreement shall be made in writing and signed by the parties hereto.
13.Enforceability.  If any provision of this Agreement shall be invalid or unenforceable, in whole or in part, then such provision shall be deemed to be modified or restricted to the extent and in the manner necessary to render the same valid and enforceable, or shall be deemed excised from this Agreement, as the case may require, and this Agreement shall be construed and enforced to the maximum extent permitted by law as if such provision had been originally incorporated herein as so modified or restricted or as if such provision had not been originally incorporated herein, as the case may be.
14.Construction.  This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California notwithstanding its conflicts of laws provisions.
15.Assignment.  The rights and obligations of the Company under this Agreement shall inure to the benefit of, and shall be binding upon, the successors and assigns of the Company.  This Agreement and the obligations created hereunder may not be assigned by the Consultant.  Any attempted assignment in violation of this Section 15 shall be null and void.
16.Notices.  All notices, requests, consents and other communications hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in person or duly sent by certified mail, 
3

postage prepaid, or by an overnight delivery service, charges prepaid, addressed to such party at the address set forth below or such other address as may hereafter be designated in writing by the addressee to the addressor:
If to the Company:
GRI Bio, Inc.
2223 Avenida De La Playa, Ste. 105
La Jolla, CA 92037
Attention: President
If to the Consultant, at the address set forth on the signature page.
Any party may from time to time change such party’s address for the purpose of notices to that party by a similar notice specifying a new address, but no such change shall be deemed to have been given until it is actually received by the party sought to be charged with its contents.
17.Waivers.  No claim or right arising out of a breach or default under this Agreement shall be discharged in whole or in part by a waiver of that claim or right unless the waiver is supported by consideration and is in writing and executed by the aggrieved party hereto or such party’s duly authorized agent.  A waiver by any party hereto of a breach or default by the other party hereto of any provision of this Agreement shall not be deemed a waiver of future compliance therewith, and such provisions shall remain in full force and effect.
(Signature page follows.)
4

IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written.
						
	GRI BIO, INC.
		
		
	By:	/s/ Sean Edwards
	Name: Sean Edwards
	Title: COO
		
		
	CONSULTANT
		
		
	/s/ Rohit Loomba
	Name: Rohit Loomba
	
	Address:

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]